Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters
- 129 Downloads
FOLFIRINOX regimen is commonly used in colorectal and more recently pancreatic cancer. However, FOLFIRINOX induces significant and dose-limiting toxic effects leading to empirical dose reduction and sometimes treatment discontinuation. Model-based FOLFIRINOX regimen optimization might help improving patients’ outcome. As a first step, the current review aims at bringing together all published population pharmacokinetics models for FOLFIRINOX anticancer drugs.
A literature search was conducted in the PubMed database from inception to February 2018, using the following terms: population pharmacokinetic(s), irinotecan, oxaliplatin, fluorouracil, FOLFIRI, FOLFOX, FOLFIRINOX. Only articles displaying nonlinear mixed effect models were included. Study description, pharmacokinetic parameter values and influential covariates are reported. For each model, the typical pharmacokinetic profile was simulated for the standard FOLFIRINOX protocol.
The FOLFIRINOX compounds have been studied only separately so far. A total of six articles were retained for 5-fluorouracil, 6 for oxaliplatin and 5 for irinotecan (also including metabolites). Either one- or two-compartment models have been described for 5-fluorouracil, while two- or three-compartment models were reported for oxaliplatin and irinotecan pharmacokinetics. Non-linear elimination was sometimes reported for 5-fluorouracil. Sex and body size were found as influential covariates for all molecules in some publications. Despite some differences in model structures and parameter values, the simulated profiles and subsequent exposure were consistent between studies.
The current review allows for a global understanding of FOLFIRINOX pharmacokinetics, and will provide a basis for further development of pharmacokinetics–pharmacodynamics–toxicity models for model-driven FOLFIRINOX protocol optimization to reach the best benefit-to-risk ratio.
KeywordsFOLFIRINOX 5-Fluorouracil Irinotecan Oxaliplatin Population pharmacokinetics Nonlinear mixed effect modelling
The authors would also like to thank the Ligue Contre le Cancer French association who generously provided a grant to Laure Deyme. We are grateful to E. Chatelut (Institut Claudius-Regaud, IUCT-Oncopole, CRCT, Université de Toulouse, Inserm, Toulouse, France) for providing us with the original data and model from the Delord et al. study.
No funding was sought for this manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal statement
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.KöhneCH, PetersGJ (2000) UFT: mechanism of drug action. Oncol Williston Park N14:13–18Google Scholar
- 3.Boisdron-CelleM, Guérin-MeyerV, CapitainO (2013) 5-fluorouracile: MSI, pharmacocinétique, DPD, TYMS et MTHFR. In: Médecine personnalisée en cancérologie digestive. Springer, Paris, pp 75–92Google Scholar
- 5.GrahamMA, LockwoodGF, GreensladeD et al (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res6:1205–1218Google Scholar
- 6.SanghaniSP, QuinneySK, FredenburgTB et al (2004) Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases Ces1a1, Ces2, and a newly expressed carboxylesterase isoenzyme, Ces3. Drug Metab Dispos32:505–511. https://doi.org/10.1124/dmd.32.5.505 CrossRefGoogle Scholar
- 7.SantosA, ZanettaS, CresteilT et al (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res6:2012–2020Google Scholar
- 9.YchouM, ConroyT, SeitzJF et al (2003) An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol14:481–489. https://doi.org/10.1093/annonc/mdg119 CrossRefGoogle Scholar
- 10.FalconeA, RicciS, BrunettiI et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nord ovest. J Clin Oncol25:1670–1676. https://doi.org/10.1200/JCO.2006.09.0928 CrossRefGoogle Scholar
- 11.ConroyT, PaillotB, FrançoisE et al (2005) Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol Off J Am Soc Clin Oncol23:1228–1236. https://doi.org/10.1200/JCO.2005.06.050 CrossRefGoogle Scholar
- 15.ConroyT, HammelP, HebbarM et al (2018) Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. Meeting ASCO 2018. https://meetinglibrary.asco.org/record/159164/abstract. Accessed 20 Jul 2018
- 22.MuellerF, BüchelB, KöberleD et al (2013) Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol71:361–370. https://doi.org/10.1007/s00280-012-2018-4 CrossRefGoogle Scholar
- 24.KhoY, JansmanFGA, PrinsNH et al (2006) Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Ther Drug Monit28:206–211. https://doi.org/10.1097/01.ftd.0000191305.64775.04 CrossRefGoogle Scholar
- 26.BastianG, BarrailA, UrienS (2003) Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs14:817–824. https://doi.org/10.1097/01.cad.0000099000.92896.5d CrossRefGoogle Scholar
- 27.PoujolS, PinguetF, YchouM et al (2007) A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. Oncol Rep18:1613–1621Google Scholar
- 40.WassermanE, CuvierC, LokiecF et al (1999) Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol Off J Am Soc Clin Oncol17:1751–1759. https://doi.org/10.1200/JCO.19126.96.36.1991 CrossRefGoogle Scholar